Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02219516 · ClinicalTrials.gov registry record · Phase 1
Mild, Moderate and Severe Renal Impairment Study
A Phase 1 study of Gout, sponsored by Ardea Biosciences.
- Completed
- Registry status
- Phase 1
- Development phase
- 31
- Enrollment target
- 4
- Study locations
NCT02219516 is a Phase 1 study of Gout that has completed, run by Ardea Biosciences. The registered enrollment target is 31 participants, below the 8,887-participant average among 34 other Gout trials with a reported enrollment target (100% lower). The trial reports 4 study locations across 4 states.
The verdict
NCT02219516, a Phase 1 study of Gout, has completed, sponsored by Ardea Biosciences.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 31 participants
- Enrollment target
- 4
- Study locations
Study Summary
This is a Phase 1, single-dose, open-label, pharmacokinetic (PK) and pharmacodynamic (PD) study of RDEA3170 in adult male subjects with mild, moderate, and severe renal impairment.
Conditions Studied
Interventions
- DRUG RDEA3170
Study Locations (4)
Colorado
- - Lakewood
Florida
- - Orlando
Minnesota
- - Minneapolis
Tennessee
- - Knoxville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 31 participants |
| Start Date | 2014-08-01 |
| Est. Completion | 2016-05-13 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02219516
The ClinicalTrials.gov registry entry for NCT02219516 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 31 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 8,887-participant average among 34 other Gout trials with a reported enrollment target (100% lower). The listed sponsor is Ardea Biosciences, which has 32 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Gout appearing as the primary indexed condition, and to 1 intervention - of which RDEA3170 is the first listed.
NCT02219516 reports 4 study locations spanning 4 distinct geographic areas - top geographies include Colorado, Florida, Minnesota.
Frequently Asked Questions
What is clinical trial NCT02219516 about?
NCT02219516 is a clinical study titled "Mild, Moderate and Severe Renal Impairment Study". This is a Phase 1, single-dose, open-label, pharmacokinetic (PK) and pharmacodynamic (PD) study of RDEA3170 in adult male subjects with mild, moderate, and severe renal impairment.
What is the current status of trial NCT02219516?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 31 participants. The study started on 2014-08-01. Estimated completion is 2016-05-13.
What conditions does trial NCT02219516 study?
This clinical trial studies the following conditions: Gout.
What interventions are being tested in trial NCT02219516?
The interventions under investigation include: RDEA3170 (DRUG).
Who is sponsoring clinical trial NCT02219516?
This trial is sponsored by Ardea Biosciences, which has 32 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02219516 being conducted?
This trial has 4 study locations across Colorado, Florida, Minnesota, Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Gout
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
PK and Safety Evaluation Study of SAP-001 in Adult Subjects With Normal and Impaired Renal Function
ACTIVE NOT RECRUITING · Phase 1
-
Safety and Pharmacodynamics of SEL-037 (Pegsiticase) in Subjects With Elevated Blood Uric Acid Levels
COMPLETED · Phase 1
-
Open Label PK, PD and DDI of Dotinurad and Allopurinol in Gout Patients with Hyperuricemia
COMPLETED · Phase 1
-
The Effect of Colchicine on the Pharmacokinetic Profile of LC350189 in Healthy Aldults.
COMPLETED · Phase 1
-
NSAID Drug Interaction Study
COMPLETED · Phase 1
-
Safety and Pharmacodynamics of SEL-212 (Pegsiticase + SEL-110) in Subjects With Elevated Blood Uric Acid Levels
COMPLETED · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.